Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials.
暂无分享,去创建一个
J. Wittes | S. Yusuf | J. Probstfield | H. Tyroler | J Wittes | H A Tyroler | S Yusuf | J Probstfield
[1] Salim Yusuf,et al. Studies of left ventricular dysfunction (SOLVD)--rationale, design and methods: two trials that evaluate the effect of enalapril in patients with reduced ejection fraction. , 1990, The American journal of cardiology.
[2] R Collins,et al. Avoidance of large biases and large random errors in the assessment of moderate treatment effects: the need for systematic overviews. , 1987, Statistics in medicine.
[3] L. Wilhelmsen,et al. Reduction of sudden deaths after myocardial infarction by treatment with alprenolol. Preliminary results. , 1974, Lancet.
[4] S. Yusuf,et al. Routine medical management of acute myocardial infarction. Lessons from overviews of recent randomized controlled trials. , 1990, Circulation.
[5] K. Swedberg,et al. EFFECT ON MORTALITY OF METOPROLOL IN ACUTE MYOCARDIAL INFARCTION A Double-blind Randomised Trial , 1981, The Lancet.
[6] C. Furberg,et al. THERAPY AND PREVENTION , 2005 .
[7] J. Wittes,et al. Overview of results of randomized clinical trials in heart disease. II. Unstable angina, heart failure, primary prevention with aspirin, and risk factor modification. , 1988, JAMA.
[8] R. Wittes,et al. Methodologic guidelines for reports of clinical trials. , 1985, Cancer treatment reports.
[9] J. Wittes,et al. Overview of results of randomized clinical trials in heart disease. I. Treatments following myocardial infarction. , 1988, JAMA.
[10] C. E. Davis,et al. Empirical Bayes estimates of subgroup effects in clinical trials. , 1990, Controlled clinical trials.
[11] Jack Cuzick,et al. Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women , 1988 .
[12] K. K. Lan,et al. Stochastically curtailed tests in long–term clinical trials , 1982 .
[13] Medical Classic. (Book Reviews: An Introduction to the Study of Experimental Medicine) , 1950 .
[14] R. Peto,et al. Beta blockade during and after myocardial infarction: an overview of the randomized trials. , 1985, Progress in cardiovascular diseases.
[15] J. Wittes,et al. Surrogate endpoints in clinical trials: cardiovascular diseases. , 1989, Statistics in medicine.
[16] M. Walsh,et al. Practolol in acute myocardial infarction. , 2009, Acta medica Scandinavica. Supplementum.
[17] Rupert G. Miller. Simultaneous Statistical Inference , 1966 .
[18] K. K. Lan,et al. Discrete sequential boundaries for clinical trials , 1983 .
[19] S. Yusuf,et al. Selection of patients for randomized controlled trials: implications of wide or narrow eligibility criteria. , 1990, Statistics in medicine.
[20] A. M. Skene,et al. TRIAL OF TISSUE PLASMINOGEN ACTIVATOR FOR MORTALITY REDUCTION IN ACUTE MYOCARDIAL INFARCTION Anglo-Scandinavian Study of Early Thrombolysis (ASSET) , 1988, The Lancet.
[21] G. Sutton,et al. A long-term prevention study with oxprenolol in coronary heart disease. , 1982, The New England journal of medicine.
[22] F. Pedersen,et al. EFFECT OF ALPRENOLOL ON MORTALITY AMONG PATIENTS WITH DEFINITE OR SUSPECTED ACUTE MYOCARDIAL INFARCTION Preliminary Results , 1979, The Lancet.
[23] J D Knoke,et al. Estimating baseline values of the variable of intervention in a clinical trial. , 1985, Controlled clinical trials.
[24] R. Simon,et al. Patient subsets and variation in therapeutic efficacy. , 1982, British journal of clinical pharmacology.